| Biomarker ID | 93 |
| PMID | 15645116 |
| Year | 2005 |
| Biomarker | SYNP02 (synaptopodin) |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Downregulated in PCa (2.4 fold ) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: 1. ALPK3 human kinase ARCHS4 coexpression. 2. NUAK1 human kinase ARCHS4 coexpression. 3. ALPK2 human kinase ARCHS4 coexpression. 4. MAPK12 human kinase ARCHS4 coexpression. . 5. MYLK4 human kinase ARCHS4 coexpression |
| Experiment | Malignant Vs Benign Tissue |
| Type of Biomarker | Diagnostic |
| Cohort | Samples were collected from 33 patients. 52 specimens were obtained, out of which 19 were paired malignant and benign, 29 were primary tumors and 4 benign tissue samples |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | Microarray Analysis |
| Clinical | No |
| Remarks | Upon analysis, 51 genes were found which were differentially expressed. 30 top genes were taken on the basis of there t-test scores and leave one out cross validation was performed with Fischer's Linear Discrimant and 90.3% accuracy was achieved while discriminating between Tumor (T) And Benign (B) Samples |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | SYNOP2 |